Source: Senvest Management, LLC
NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- This press release is being disseminated by Senvest Management, LLC, as agent for and on behalf of the funds for whom it acts as investment manager or advisor (“Senvest”), as required by National Instrument 62-104 of the Canadian Securities Administrators in connection with Senvest’s acquisition of 319,900 common shares in the capital of Cannimed Therapeutics Inc. (“CMED”) after a take-over bid had commenced for the shares of CMED and which acquisition, when added to Senvest’s previously held securities, constitute 5% or more of the outstanding common shares. Currently, Senvest has control or direction over 1,601,500 common shares of CMED, representing approximately 6.9% of CMED’s currently issued and outstanding common shares. The acquisition of the common shares by Senvest was made in the ordinary course for investment purposes and effected through facilities of the Toronto Stock Exchange.
Senvest exercises control or direction over all of the securities referred to in this news release on behalf of funds and its clients for investment purposes. Depending on market conditions and other factors that Senvest may deem material to its investment decisions, Senvest may from time to time in the future increase or decrease its ownership of, or control or direction over, the common shares or other securities of CMED, through market transactions, private agreements or otherwise, subject to the terms of such securities and applicable law.
For further information, please contact:
Senvest Management, LLC, Compliance Department
E-Mail Address: Compliance@Senvest.com